

Treatment of Chronic HCV in End-Stage Renal Disease: Advances in 2016

PROGRAM AGENDA

6:30 – 7:00pm	Registration and Check-in
7:00 – 7:15pm	Welcome and Introductions Dinner is served
7:15 – 8:15pm	Presentation <ul style="list-style-type: none">• Epidemiology of HCV in Patients on Hemodialysis Patients• Association of Diabetes Mellitus (DM) and HCV Infection• HCV and Kidney Transplantation• Diagnosis and Evaluation of the Patient with Hepatitis C• Liver Biopsy and Fibrosis Testing• Current Treatment Regimes for Hepatitis C Patients• Recommended Regimens for Patients with Severe Renal Impairment• Outcomes and Recommendations for current Clinical Trials• Review and Re-Cap• Question and Discussion
8:15 – 8:30pm	Informal Networking
8:30pm	Program adjourns

LEARNING OBJECTIVES

As a result of participating in this activity, participants should be able to:

- Describe the epidemiology of Hepatitis C (HCV) in kidney disease patients, especially those undergoing hemodialysis (HD)
- Explain the various risk factors for HCV infection among HD patients
- Explore HCV and Risk of Death in Long-Term Hemodialysis Patients
- See how HCV can be a cause of Renal Disease and other Immune Complex Disorders
- Investigate the impact of HCV on kidney transplant patients
- Implement the current diagnostic approaches for HCV and the efficacy of each
- Utilize the benefits and limitations of liver biopsy and fibrosis testing in workup of kidney patients

- Translate the widely held medical pearls in the evaluation of HCV infection in kidney disease
- Explore the latest research findings on the treatment of HCV to provide therapeutic options of patients with kidney disease
- Discuss therapeutic and patient management options through a series of clinical case presentations
- Screen, diagnose and effectively treat appropriate kidney patients and know when and how to refer to a Hepatologist for more advanced liver care